Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Can the Health of the Nation Outcome Scales for Children and Adolescents predict the necessity of inpatient stay during assertive community treatment?

Urben S, Mantzouranis G, Baier V, Halfon O, Villard E, Holzer L.

Psychiatry Res. 2016 Jun 14;242:345-348. doi: 10.1016/j.psychres.2016.06.018. [Epub ahead of print]

PMID:
27341331
2.

Clinical Utility of the 2 New Scales of the Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA): A Naturalistic, Prospective Study in a Psychiatric Unit for Adolescents.

Urben S, Pihet S, Graap C, Baier V, Dyson C, Courosse S, Holzer L.

J Psychiatr Pract. 2015 May;21(3):232-40. doi: 10.1097/PRA.0000000000000071.

PMID:
25955267
3.

Predictors and Moderators of Clinical Outcomes in Adolescents with Severe Mental Disorders After an Assertive Community Treatment.

Urben S, Baier V, Mantzouranis G, Pigois E, Graap C, Dutoit F, Cherix-Parchet M, Henz C, Faucherand A, Senent E, Holzer L.

Child Psychiatry Hum Dev. 2015 Dec;46(6):997-1005. doi: 10.1007/s10578-015-0537-z.

PMID:
25700848
4.

The French adaptation of the Health of the Nation Outcome Scale for Children and Adolescents Self-Rated Form (F-HoNOSCA-SR): validation and clinical routine use.

Urben S, Baier V, Mantzouranis G, Schwery J, Mahi C, Courosse S, Guignet B, Halfon O, Holzer L.

Psychiatry Res. 2014 Aug 15;218(1-2):229-35. doi: 10.1016/j.psychres.2014.04.004. Epub 2014 Apr 12.

PMID:
24751378
5.

Influence of CRTC1 polymorphisms on body mass index and fat mass in psychiatric patients and the general adult population.

Choong E, Quteineh L, Cardinaux JR, Gholam-Rezaee M, Vandenberghe F, Dobrinas M, Bondolfi G, Etter M, Holzer L, Magistretti P, von Gunten A, Preisig M, Vollenweider P, Beckmann JS, Pralong FP, Waeber G, Kutalik Z, Conus P, Bochud M, Eap CB; ODEX team.

JAMA Psychiatry. 2013 Oct;70(10):1011-9. doi: 10.1001/jamapsychiatry.2013.187.

PMID:
23925723
6.

Treatment motivation in adolescents with psychosis or at high risk: determinants and impact on improvements in symptoms and cognitive functioning, preliminary results.

Pihet S, Moses Passini C, Holzer L.

Psychother Res. 2013;23(4):464-73. doi: 10.1080/10503307.2013.794398. Epub 2013 May 8.

PMID:
23656510
7.

A randomized controlled trial of the effectiveness of computer-assisted cognitive remediation (CACR) in adolescents with psychosis or at high risk of psychosis.

Holzer L, Urben S, Passini CM, Jaugey L, Herzog MH, Halfon O, Pihet S.

Behav Cogn Psychother. 2014 Jul;42(4):421-34. doi: 10.1017/S1352465813000313. Epub 2013 May 1.

PMID:
23631951
8.

Computer-assisted cognitive remediation in adolescents with psychosis or at risk for psychosis: a 6-month follow-up.

Urben S, Pihet S, Jaugey L, Halfon O, Holzer L.

Acta Neuropsychiatr. 2012 Dec;24(6):328-35. doi: 10.1111/j.1601-5215.2012.00651.x. No abstract available.

PMID:
25287174
9.

Early tailored assertive community case management for hard-to-engage adolescents suffering from psychiatric disorders: an exploratory pilot study.

Baier V, Favrod J, Ferrari P, Koch N, Holzer L.

Early Interv Psychiatry. 2013 Feb;7(1):94-9. doi: 10.1111/j.1751-7893.2012.00380.x. Epub 2012 Jul 5.

PMID:
22765257
10.

Cognitive efficacy of quetiapine in early-onset first-episode psychosis: a 12-week open label trial.

Urben S, Baumann P, Barcellona S, Hafil M, Preuss U, Peter-Favre C, Clarke S, Halfon O, Holzer L.

Psychiatr Q. 2012 Sep;83(3):311-24. doi: 10.1007/s11126-011-9201-3.

PMID:
22101738
11.

Deteriorated visual backward masking in the shine-through effect in adolescents with psychosis.

Holzer L, Jaugey L, Chinet L, Herzog MH.

J Clin Exp Neuropsychol. 2009 Aug;31(6):641-7. doi: 10.1080/13803390802438454. Epub 2008 Nov 24.

PMID:
19031325
12.

Adolescent substance-use assessment: methodological issues in the use of the Adolescent Drug Abuse Diagnosis (ADAD).

Chinet L, Plancherel B, Bolognini M, Holzer L, Halfon O.

Subst Use Misuse. 2007;42(10):1505-25. Retraction in: Subst Use Misuse. 2015;50(10):1371.

PMID:
17918022
13.

Olanzapine and blepharoclonus.

Sofia-Gabrion CK, Ali Yahia Y, Holzer L.

J Clin Psychiatry. 2007 Sep;68(9):1443-4. No abstract available.

PMID:
17915987
14.

Detection of cognitive impairment with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in adolescents with psychotic symptomatology.

Holzer L, Chinet L, Jaugey L, Plancherel B, Sofia C, Halfon O, Randolph C.

Schizophr Res. 2007 Sep;95(1-3):48-53. Epub 2007 Jul 16.

PMID:
17629676
15.

Selective serotonin reuptake inhibitors in adolescent depression still controversial.

Holzer L, Baumann P.

J Clin Psychopharmacol. 2007 Jun;27(3):325-6; author reply 326. No abstract available.

PMID:
17502798
16.

Adolescent Drug Abuse Diagnosis (ADAD) vs. Health of Nation Outcome Scale for Children and Adolescents (HoNOSCA) in clinical outcome measurement.

Holzer L, Tchemadjeu IK, Plancherel B, Bolognini M, Rossier V, Chinet L, Halfon O.

J Eval Clin Pract. 2006 Oct;12(5):482-90.

PMID:
16987110
17.

Risperidone-induced symptomatic hyperprolactinaemia in adolescents.

Holzer L, Eap CB.

J Clin Psychopharmacol. 2006 Apr;26(2):167-71.

PMID:
16633146
18.

Sertraline and gastrointestinal bleeding in an adolescent girl.

Holzer L, Halfon O.

J Child Adolesc Psychopharmacol. 2006 Feb-Apr;16(1-2):1-2. No abstract available.

PMID:
16553521
19.

Community introduction of practice parameters for autistic spectrum disorders: Advancing early recognition.

Holzer L, Mihailescu R, Rodrigues-Degaeff C, Junier L, Muller-Nix C, Halfon O, Ansermet F.

J Autism Dev Disord. 2006 Feb;36(2):249-62.

PMID:
16447011
20.

Aripiprazole and suicidality.

Holzer L, Eap CB.

Int Clin Psychopharmacol. 2006 Mar;21(2):125-6.

PMID:
16421465
Items per page

Supplemental Content

Loading ...
Write to the Help Desk